Design of new protocols. Role of molecular biology units?;Conception de protocoles nouveaux. Quels laboratoires de biologie moléculaire?

Bulletin du Cancer

Volumn 95, Issue 10, 2008, Pages 1003-1005

  Milano, Gérard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Clinical trials; Molecular biology; Predictive markers; Targeted therapy

Indexed keywords

CETUXIMAB; EVEROLIMUS; PANITUMUMAB;

BREAST CANCER; COLORECTAL CANCER; GENE AMPLIFICATION; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; SHORT SURVEY;

ANTINEOPLASTIC AGENTS; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; MOLECULAR BIOLOGY; NEOPLASMS; PROTEIN KINASES;

EID: 56149103424     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0735     Document Type: Short Survey

References (11)

1. Kwak E, Clark JW, Chabner B. Targeted agents : the rules of combination. Clin Cancer Res 2007 ; 13 : 5232-7.
2. Doyle DM, Miller KD. Development of new targeted therapies for breast cancer. Cancer Treat Res 2008 ; 141 : 119-34.
3. Pickering L, Rudman S, Ross PJ, Leslie MD. Targeted therapy in colorectal carcinoma : more than a theory. Colorectal Dis 2008 ; 10 : 209-18.
4. Milano G. Predictive factors of response to targeted therapies : the example of colorectal cancer. Bull Cancer 2007 ; 94(7) : F227-F230.
5. Goulart B, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA. Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res 2007 ; 13 : 6719-26.
6. De Azambuja E, Cardoso F, Meirsman L, et al. The new generation of breast cancer clinical trials : the right drug for the right target. Bull Cancer 2008 ; 95(3) : 352-7.
7. Mounier N, Vignot S, Spano JP. Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor. Bull Cancer 2006 ; 93(11) : 1139-43.
8. Eberhard DA, Giaccone G, Johnson BE, Non-Small-Cell Lung Cancer Working Group. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group : standardization for use in the clinical trial setting. J Clin Oncol 2008 ; 26 : 983-94.
9. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008 ; 26 : 1626-34.
10. Lièvre A, Laurent-Puig P. Predictive factors of response to anti-EGFR treatments in colorectal cancer. Bull Cancer 2008 ; 95(1) : 133-40.
11. Laurent-Puig P, Lièvre A, Ducreux M, Loriot MA. Le point de vue du biologiste sur la pharmacogénétique dans le cancer colorectal. Bull Cancer 2008 ; 95(10) : 935-942.